PHILADELPHIA — The Basser Center for BRCA at Penn Medicine’s Abramson Cancer Center, the world’s first comprehensive center aimed at advancing research, treatment, and prevention of BRCA-related cancers, has announced Maria Jasin, PhD, as the recipient of the sixth annual Basser Global Prize. Jasin is a member of the Developmental Biology Program at Memorial Sloan Kettering Cancer Center and a professor at the Weill Graduate School of Medical Sciences at Cornell University.
Each year, the Basser Global Prize recognizes a leading scientist who has conceptually advanced BRCA1/2-related research. Individuals with mutations in the BRCA1 and BRCA2 genes are at an increased risk of breast, ovarian, pancreatic and other cancers.
Jasin’s research has helped define the roles of BRCA1 and BRCA2 in DNA repair. Her discoveries have led to numerous investigative efforts worldwide, resulting in a greater understanding of how cancer develops and in new therapies that can lengthen the lives of cancer patients.
“We are honored to recognize Dr. Jasin for her accomplishments, which have been transformational in our understanding of how cancer is suppressed by genes such as BRCA1 and BRCA2,” said Susan Domchek, MD, executive director of the Basser Center for BRCA. “Her work has resulted in insights into the mechanisms by which BRCA1 and BRCA2 mutations lead to cancer. This knowledge has been essential in considering how to target tumors with BRCA1/2 mutations.”
Twenty years ago, Jasin’s laboratory discovered that BRCA1 and BRCA2 are critical for the repair of damaged DNA through a process known as homologous recombination — which occurs when a damaged DNA molecule copies genetic material from an undamaged similar molecule (in non-homologous repair, breaks are fixed without such a template). Homologous recombination is used by cells to repair breaks that occur on both strands of DNA, known as double-strand breaks (DSB), which can result from exogenous causes, such as ionizing radiation, and also can spontaneously occur during DNA replication. The body’s inability to repair damaged DNA is responsible for many human diseases, especially cancer.
While homologous recombination was long recognized as an important DSB-repair pathway in organisms such as E. coli and yeast, non-homologous processes were thought to be solely responsible for repair of DSBs in mammalian cells. Jasin’s lab upended this presumption by generating a single DSB in the genome of a mammalian cell line and then examining the repair process. These experiments convincingly showed that in addition to non-homologous repair, homologous repair is a major repair pathway in mammalian cells. A substantial fraction of total repair events is now known to arise from homologous repair.
In a subsequent finding, Jasin discovered that while both BRCA1 and BRCA2 are critical for homologous recombination to repair DNA breaks, they act at different steps along the pathway. As a result, BRCA1- and BRCA2-related tumors have distinct as well as overlapping second-site mutations that can influence therapy resistance. One of Jasin’s current research efforts is on understanding DNA repair in the breast at different developmental stages and contexts.
The award presentation will be accompanied by Jasin’s keynote address at the seventh annual Basser Center for BRCA Scientific Symposium on May 7, 2019. The Basser Global Prize provides $100,000 in unrestricted support of the winner's BRCA1/2-related research efforts, a Basser trophy, and a $10,000 cash prize, which will be awarded at the symposium.
“It is very humbling to be chosen for this honor by the Basser Center, which in a short time has become world-renowned for its efforts to help patients with inherited BRCA1/2 mutations,” Jasin said. “The Basser Global Prize will be integral in making the best use of the molecular genetic systems we have developed for understanding the role of homologous recombination in protecting the genome. Our aim is to contribute to a better understanding of BRCA-related cancers and potentially achieve their reversal through treatments and genetic correction.”
Jasin obtained her PhD from the Massachusetts Institute of Technology and was a postdoctoral researcher at the University of Zürich and Stanford University. Her research accomplishments have led to many honors and recognitions, including election to the National Academies of Sciences and Medicine and the American Academy of Arts and Sciences. She has organized several timely scientific conferences, including those sponsored by AACR and Cold Spring Harbor Laboratory, and has participated in the National Academies’ 2015 and 2018 Human Genome Editing Summits.
The Basser Center was established in 2012 with a $25 million gift from University of Pennsylvania alumni Mindy and Jon Gray in memory of Mindy Gray’s sister Faith Basser, who died of ovarian cancer at age 44. Last year, the Grays committed another $21 million to support research to improve treatment and prevention strategies for hereditary cancers. The Basser Global Prize was established and subsequently endowed by Shari Basser Potter and Leonard Potter.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation’s first medical school) and the University of Pennsylvania Health System, which together form a $8.9 billion enterprise.
The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $496 million awarded in the 2020 fiscal year.
The University of Pennsylvania Health System’s patient care facilities include: the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center—which are recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report—Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; and Pennsylvania Hospital, the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is powered by a talented and dedicated workforce of more than 44,000 people. The organization also has alliances with top community health systems across both Southeastern Pennsylvania and Southern New Jersey, creating more options for patients no matter where they live.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2020, Penn Medicine provided more than $563 million to benefit our community.